Examining the link between donor telomere length and outcomes in acute leukemia patients after stem cell transplantation
The First Affiliated Hospital, Zhejiang University School of Medicine
This study is trying to see if the length of telomeres in blood from stem cell donors can affect how well patients with acute leukemia do after their transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Ages | 5 Years to 90 Years |
| Sex | All |
| Sponsor | Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06076226 on ClinicalTrials.gov |
What this trial studies
This observational study analyzes the relationship between donor leukocyte telomere length and the prognosis of patients with acute leukemia who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). It includes patients aged 5 years and older who achieved complete remission and full donor chimerism post-transplant. The study assesses donor blood samples for telomere length prior to granulocyte colony-stimulating factor mobilization. The research is conducted at two major hospitals in China, ensuring ethical compliance and informed consent.
Who should consider this trial
Good fit: Ideal candidates are patients aged 5 years and older with acute leukemia who have undergone their first allo-HSCT and achieved complete remission.
Not a fit: Patients with non-acute leukemia diagnoses or those who did not achieve full donor chimerism after transplantation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into how donor characteristics influence patient outcomes, potentially leading to improved transplant strategies.
How similar studies have performed: While similar studies have explored donor characteristics in transplantation, this specific focus on telomere length in acute leukemia is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 5 years * First allo-HSCT from matched related, unrelated, or haploidentical donors * Achievement of complete remission after allo-HSCT * Donor blood sample collection before granulocyte colony-stimulating factor mobilization Exclusion Criteria * Non-acute leukemia diagnoses, including acute myeloid leukemia, acute lymphocytic leukemia, and mixed phenotype acute leukemia * Failure to achieve engraftment with full donor chimerism after allo-HSCT * Inability to extract DNA for telomere length analysis.
Where this trial is running
Hangzhou, Zhejiang
- Clinical research ethics committee of the first affiliated hospital, college of medicine, zhejiang University — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: He Huang, PhD&MD
- Email: huanghe@zju.edu.cn
- Phone: +86 13605714822
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.